Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Average Recommendation of “Hold” from Analysts

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) has been given a consensus recommendation of “Hold” by the four brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $14.50.

VRCA has been the subject of several recent analyst reports. Zacks Research upgraded shares of Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. HC Wainwright assumed coverage on shares of Verrica Pharmaceuticals in a research note on Tuesday, May 26th. They issued a “buy” rating and a $12.00 price target for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, July 15th. Finally, Wall Street Zen lowered shares of Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th.

Institutional Investors Weigh In On Verrica Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Armistice Capital LLC lifted its stake in shares of Verrica Pharmaceuticals by 75.1% in the 4th quarter. Armistice Capital LLC now owns 1,118,925 shares of the company’s stock valued at $9,298,000 after purchasing an additional 479,732 shares during the last quarter. State Street Corp increased its position in shares of Verrica Pharmaceuticals by 14.1% during the 4th quarter. State Street Corp now owns 23,481 shares of the company’s stock worth $195,000 after purchasing an additional 2,900 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in shares of Verrica Pharmaceuticals during the 4th quarter worth about $188,000. HRT Financial LP purchased a new stake in Verrica Pharmaceuticals in the 4th quarter valued at about $144,000. Finally, Beck Mack & Oliver LLC purchased a new stake in Verrica Pharmaceuticals in the 4th quarter valued at about $100,000. Hedge funds and other institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Stock Up 6.6%

NASDAQ VRCA opened at $4.99 on Thursday. Verrica Pharmaceuticals has a 52 week low of $3.28 and a 52 week high of $9.82. The company has a quick ratio of 1.33, a current ratio of 1.45 and a debt-to-equity ratio of 0.18. The business’s fifty day simple moving average is $5.64 and its 200-day simple moving average is $5.90. The firm has a market cap of $85.73 million, a PE ratio of -2.99 and a beta of 1.49.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a clinical?stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off?label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next?generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.